We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02406677
First Posted: April 2, 2015
Last Update Posted: October 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Duke Clinical Research Institute
Information provided by (Responsible Party):
AstraZeneca
March 30, 2015
April 2, 2015
October 23, 2017
June 5, 2015
October 1, 2017   (Final data collection date for primary outcome measure)
  • Major Adverse Cardiovascular Events [ Time Frame: 12 months ]
    To determine if patient copayment reduction leads to lower risk of MACE (composite of death, MI, and stroke) at 1 year after discharge.
  • Long Term Persistence to P2Y12 receptor inhibitor [ Time Frame: 12 months ]
    To determine if patient copayment reduction leads to higher long-term persistence of any P2Y12 receptor inhibitor at 1 year after discharge.
Same as current
Complete list of historical versions of study NCT02406677 on ClinicalTrials.gov Archive Site
  • P2Y12 receptor inhibitor selection [ Time Frame: 12 months ]
    To evaluate whether reducing patient copayments for both generic and brand P2Y12 receptor inhibitor options affects medication selection at discharge.
  • Healthcare Resource Utilization [ Time Frame: 12 months ]
    To assess the impact of copayment reduction on the total cost of health care for patients after myocardial infarction.
Same as current
Not Provided
Not Provided
 
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess the impact of copayment reduction by equalizing the copayment of clopidogrel and ticagrelor. ARTEMIS will assess prescribing patterns, patient medication adherence, and clinical outcomes up to one year. We hypothesize that reducing out--of--pocket cost for P2Y12 receptor inhibitor will lead to improved adherence. Additionally, copayment reduction of both generic and brand antiplatelet agents may lead to a reduction in MACE risk. This is in part due to greater adherence to an evidence--based secondary prevention medication. Additionally the reduction in MACE may reflect greater selection of a more potent antiplatelet agent that has been shown to reduce MACE in randomized clinical trials, as provider choice of antiplatelet therapy will be primarily driven by risk- benefit assessment rather than the cost burden to the patient.
ARTEMIS is a prospective, cluster-randomized clinical trial that will evaluate whether patient copayment elimination significantly influences antiplatelet therapy selection and long-term adherence, as well as patient outcomes and overall cost of care after acute myocardial infarction. Approximately 11,000 patients with ST-elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) will be enrolled at the approximately 300 hospitals in this study. Study sites selected for ARTEMIS will be geographically diverse, and will represent a diversity of hospital types and capabilities (e.g., teaching hospital, community hospital, etc). After institutional review board (IRB) approval of the study, each hospital will be randomized into either the intervention arm or the control arm. Hospitals randomized to the intervention arm will have the opportunity to offer enrolled patients either clopidogrel (generic P2Y12 receptor inhibitor option) or ticagrelor (brand P2Y12 receptor inhibitor option) without patient contribution to copayment in the next 12 months after the index MI discharge. Hospitals in the control arm will provide care per usual clinical routine. Notably, for both intervention and control arms, all patient management decisions (including the choice of antiplatelet therapy) are completely at the discretion of the care providers. Duration of antiplatelet therapy will also be at the discretion of care providers. All enrolled patients will be followed up to 15 months after index MI discharge to collect data on longitudinal treatment patterns and outcomes. Primary and secondary endpoints will be assessed at 12 months. An additional three months of follow up will assess for antiplatelet persistence and clinical events after discontinuation of the copayment intervention. Centralized follow-up will be conducted every 3 months via telephone or web-based contact.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Cost Sharing, Acute Coronary Syndrome
Other: Study voucher card
Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
  • Experimental: Copayment Intervention Arm
    Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
    Intervention: Other: Study voucher card
  • No Intervention: Usual Care Arm
    For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
11001
October 1, 2017
October 1, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients are eligible to be included in the study if they meet all of the following criteria:

  • are ≥ 18 years of age
  • have been diagnosed with STEMI or NSTEMI during the index hospitalization
  • be treated with a P2Y12 receptor inhibitor at the time of enrollment
  • have U.S. based health insurance coverage with prescription drug benefit
  • have been fully informed and are able to provide written consent for longitudinal follow-up

Exclusion Criteria:

Patients are excluded if they meet any of the following criteria:

  • have a history of prior intracranial hemorrhage
  • have any contraindications to P2Y12 receptor inhibitor therapy at discharge
  • involvement in another research study that specifies the type and duration of P2Y12 receptor inhibitor use within the next 12 months.
  • have a life expectancy of less than one year
  • have plans to move outside the US in the next year
Sexes Eligible for Study: All
18 Years to 130 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Puerto Rico,   United States
 
 
NCT02406677
D5130R00030
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Duke Clinical Research Institute
Principal Investigator: Tracy Wang, MD, MHS, MSc Duke University
Study Chair: Eric Peterson, MD, MPH, FAHA, FACC Duke University
AstraZeneca
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP